



LETTER TO EDITOR

Psychological Therapies: The Missing Link in Improving Treatment Adherence in Patients with β -thalassemia Major

Amir Emami Zeydi¹, Hossein Karimi Moonaghi^{2,3*}, Abbas Heydari^{2,3}

¹Student Research Committee, PhD candidate in Nursing, Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran

²Evidence- Based Care Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

³Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran

ARTICLE INFO

Article History:

Received: 12.08.2017

Accepted: 01.10.2017

*Corresponding author:

Hossein Karimi Moonaghi,
School of Nursing and Midwifery,
Mashhad University of Medical
Sciences, Ebne-Sina Street, Mashhad,
Razavi Khorasan, Iran
Tel: +98 51 38511511
Fax: +98 51 385907313
Email: karimih@mums.ac.ir

Please cite this article as: Emami Zeydi A, Karimi Moonaghi H, Heydari A. Psychological Therapies: The Missing Link in Improving Treatment Adherence in Patients with β -thalassemia Major. IJBC 2017; 9(4): 130-131.

Dear Editor

β -Thalassemia Major (β -TM) is the most commonly inherited hemolytic anemia. Patients with β -TM require lifelong adherence to distressing treatment regimen, including regular blood transfusions, daily chelation therapy and frequent medical supervision.¹ Similar to other chronic diseases requiring long-life treatment, adherence to treatment is a major concern for β -TM patients.² It has been revealed that poor adherence to therapeutic regimen in β -TM patients is associated with an increased risk of complications, unnecessary health cost, and mortality and morbidity rates. Despite the clinical importance of adherence to treatment in patients with β -TM, poor adherence remains a prevalent and persistent problem in these patients.^{2,3} Also, to date, cost-effective interventions to improve adherence to therapeutic regimens in β -TM patients are yet unavailable.⁴

Life-long treatment could make these patients more susceptible to wide array of psychological and psychosocial problems.¹ Evidence clearly shows the high prevalence of psychological problems among β -TM patients.⁵ It has been shown that up to 80% of patients with β -TM, at least, from one psychiatric disorder such as depression, body dimorphic disorders, obsessive-compulsive disorder, anxiety disorders, and psychosis. Also, most of these

patients experience some restrictions on their social and occupational functioning.⁵⁻⁷ Additionally, available evidence suggests that patients' adherence behavior to the prescribed medical treatment regimen can be modified by psychological factors. It has been shown that psychological impairment is a significant predictor of non-adherence among patients with β -TM.^{8,9} It is believed that psychological treatments such as psychoeducation, cognitive therapy, problem-solving skills training, distress management, psychodynamic psychotherapy, behavioral therapy and optimization of self-regulatory processes may improve the quality of life of patients with β -TM through better coping with disease, fulfil roles, and their increased adherence to treatment. Also, those interventions are simply available at hospital or community setting and most of them are applicable for a range of different ages.^{5,7,8,10} Despite its potential benefits, the results of a current systematic review indicate that there is no study addressing the effect of psychological therapies in patients with β -TM.¹⁰

In sum, it goes without saying that patients' adherence to treatment in β -TM is a very important topic and many known and unknown psychological factors affect it. Nevertheless, the evidence supporting the effectiveness

of psychological therapies on adherence to treatment among these patients is dearth. Therefore, we believe that further well designed clinical trials should be carried out with a particular focus on psychological interventions to investigate the efficacy of such interventions on the levels of adherence to treatment in patients with β -TM that may result in better clinical outcomes.

Conflict of Interest: None declared.

References

1. Mednick L, Yu S, Trachtenberg F, Xu Y, Kleinert DA, Giardina PJ, et al. Symptoms of depression and anxiety in patients with thalassemia: prevalence and correlates in the thalassemia longitudinal cohort. *Am J Hematol*. 2010; 85(10):802-5. doi: 10.1002/ajh.21826. PubMed PMID: 20806230.
2. Emami Zeydi A, Heydari A, Karimi Moonaghi H. Regular Reminding of the Potential Serious Complications of Poor Adherence to Treatment: A Strategy for Improving Treatment Adherence in Beta-Thalassemia Major Patients. *Int J Pediatr* 2017; 5(12): 6201-2. doi:10.22038/ijp.2017.25718.2190.
3. Darvishi Khezri H, Emami Zeydi A, Sharifi H, Jalali H. Is Vitamin C Supplementation in Patients with β -Thalassemia Major Beneficial or Detrimental? *Hemoglobin*. 2016;40(4):293-4. doi: 10.1080/03630269.2016.1190373. PubMed PMID: 27492769.
4. Lehane E, McCarthy G. Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper. *Int J Nurs Stud*. 2007; 44(8):1468-77. doi: 10.1016/j.ijnurstu.2006.07.010. PubMed PMID: 16973166.
5. Messina G, Colombo E, Cassinerio E, Ferri F, Curti R, Altamura C, et al. Psychosocial aspects and psychiatric disorders in young adult with thalassemia major. *Intern Emerg Med*. 2008; 3(4):339-43. doi: 10.1007/s11739-008-0166-7. PubMed PMID: 18551386.
6. Nasiri M, Hosseini SH, Shahmohammadi S. Mental health status in patients with Thalassemia major in Iran. *J Pediatr Rev*. 2014; 2(1):55-61. doi: 10.7508/JPR-V2-N1-55-61.
7. Behdani F, Badiie Z, Hebrani P, Moharreri F, Badiie AH, Hajivosugh N, et al. Psychological aspects in children and adolescents with major thalassemia: A case-control study. *Iran J Pediatr*. 2015; 25(3):e322. doi: 10.5812/ijp.25(3)2015.322. PubMed PMID: 26199704.
8. Al-Kloub MI, A Bed MA, Al Khawaldeh OA, Al Tawarah YM, Froelicher ES, et al. Predictors of non-adherence to follow-up visits and deferasirox chelation therapy among jordanian adolescents with Thalassemia major. *Pediatr Hematol Oncol*. 2014; 31(7):624-37. doi: 10.3109/08880018.2014.939792. PubMed PMID: 25116329.
9. Trachtenberg F, Vichinsky E, Haines D, Pakbaz Z, Mednick L, Sobota A, et al. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. *Am J Hematol*. 2011; 86(5):433-6. doi: 10.1002/ajh.21993. PubMed PMID: 21523808.
10. Anie KA, Massaglia P. Psychological therapies for thalassaemia. *Cochrane Database Syst Rev*. 2014; 3:CD002890. doi: 10.1002/14651858.CD002890.pub2. PubMed PMID: 24604627.